Does Priority Health Cover Vyvanse?

What Is Vyvanse and Why Does Coverage Get Complicated?

Vyvanse is a central nervous system stimulant classified as a Schedule II controlled substance by the Drug Enforcement Administration. The FDA approved lisdexamfetamine dimesylate in 2007 for ADHD and in 2015 for moderate-to-severe binge eating disorder (BED) in adults. [1] Because it is a controlled substance with significant misuse potential, insurers add extra administrative layers beyond what they apply to most non-controlled medications.

The Schedule II Factor

Schedule II status means the DEA limits refills, requires paper or electronic prescriptions in most states, and requires pharmacies to track dispensing carefully. [2] Insurers treating Schedule II drugs often require annual or biannual re-authorization, even if a patient has been stable on therapy for years. Priority Health is no exception.

The Brand-vs.-Generic Pricing Dynamic

Branded Vyvanse carried a list price exceeding $400 per month before generic entry. [3] The FDA approved the first generic lisdexamfetamine products in 2023, which has pushed insurers to place the brand on higher tiers or restrict it in favor of the lower-cost generic. [4] If your prescriber writes "Vyvanse" specifically and your pharmacy dispenses the brand, expect stricter coverage requirements than for the generic formulation.

Diagnosis Matters for Coverage

Priority Health, like most insurers, ties coverage criteria to FDA-approved indications. A prescription for ADHD and a prescription for BED may face different criteria, different step-therapy requirements, and different documentation needs, even though both are for the same molecule.

How Priority Health Formulary Tiers Work

Most Priority Health commercial plans use a five-tier formulary. Generic drugs land on Tier 1 or 2; preferred brand-name drugs sit on Tier 3; non-preferred brands occupy Tier 4; specialty drugs fill Tier 5. [5]

Where Vyvanse Typically Falls

On most Priority Health commercial formularies, branded Vyvanse lands on Tier 3 or Tier 4, which translates to co-pays between $50 and $150 per 30-day supply after the deductible, depending on your specific plan design. Generic lisdexamfetamine often lands on Tier 2, with co-pays in the $10, $40 range.

The exact tier for your plan is confirmed in the Summary of Benefits and Coverage document your employer receives each year, or directly in the Priority Health member portal under "drug coverage."

Medicaid vs. Commercial Tiers

Priority Health also administers Michigan Medicaid managed care plans. Michigan Medicaid covers lisdexamfetamine, but the fee schedule and prior authorization rules differ from commercial plans. The Michigan Department of Health and Human Services publishes its preferred drug list separately. [6] If you are enrolled in Priority Health's Medicaid product, ask specifically about Medicaid criteria rather than commercial plan criteria.

Prior Authorization Requirements for Vyvanse

Prior authorization (PA) is the formal process by which your prescriber submits clinical documentation to Priority Health before the plan agrees to pay. For Vyvanse, this almost always applies.

What Documentation Priority Health Typically Requests

Priority Health PA criteria for stimulants typically require:

• A confirmed diagnosis of ADHD (DSM-5 criteria) or moderate-to-severe BED (DSM-5 criteria) from a licensed clinician
• Documentation of the patient's age (ADHD coverage for children is often approved from age 6 upward, consistent with FDA labeling [1])
• Confirmation that step therapy requirements have been met, or a reason why they cannot be
• For adults, often a statement that the prescribing provider is an MD, DO, NP, or PA with prescribing authority for controlled substances

The American Academy of Pediatrics 2019 clinical practice guideline recommends FDA-approved medications, including stimulants, as first-line pharmacotherapy for school-age children with ADHD, a statement that carries weight in PA appeals. [7]

How Long PA Approval Takes

Under federal rules for urgent requests, insurers must respond within 72 hours; for standard PA, within 3 business days for commercial plans. [8] Michigan state law may impose additional timelines. Your prescriber's office can flag a PA as "urgent" if you are running out of medication.

PA for the BED Indication

If your prescription is for BED rather than ADHD, Priority Health's criteria will focus on BMI, binge frequency (typically ≥3 episodes per week over ≥3 months per DSM-5 criteria), absence of compensatory behaviors consistent with bulimia, and whether a behavioral intervention has been attempted. The clinical literature supporting lisdexamfetamine for BED is strong: the key phase III trial (McElroy et al., 2016; N=383) showed a 50 mg and 70 mg dose produced statistically significant reductions in binge-eating days per week vs. Placebo (P<0.001). [9] Presenting this trial to reviewers during an appeal can help.

Step Therapy: The Stimulant You May Need to Try First

Step therapy (also called "fail first") requires you to try a less expensive drug before the insurer will approve a more expensive one. For Vyvanse, Priority Health commonly requires a trial of a generic stimulant.

Which Drugs Count as Step Therapy

Amphetamine salts (mixed amphetamine salts, the generic of Adderall) and methylphenidate (generic Ritalin/Concerta) are the two drug classes most often required. Specifically:

• Mixed amphetamine salts IR or XR, typically for 30 days at an adequate dose
• Methylphenidate IR or ER, typically for 30 days at an adequate dose

Some plans accept failure of one class; others require failure of both. "Failure" means documented adverse effects, inadequate response, or a contraindication.

Exemptions to Step Therapy

Michigan law and federal rules for marketplace plans include step-therapy exemption provisions. [10] You may bypass step therapy if:

1. You tried and failed those agents in the past 12 months (prior history counts).
2. A contraindication exists (e.g., known intolerance, cardiac contraindication documented by a cardiologist).
3. The step-therapy requirement would cause clinically significant delay in care for a condition that is life-threatening or causes irreversible harm.

Your prescriber must document the exemption reason in writing and submit it with the PA request.

What Vyvanse Actually Costs With Priority Health

Cost depends on four variables: your plan's tier for this drug, whether you have met your deductible, your plan's cost-sharing structure after the deductible, and whether you use a manufacturer coupon.

After the Deductible: Typical Co-Pay Ranges

| Formulary Tier | Estimated Monthly Co-Pay (post-deductible) | |---|---| | Tier 2 (generic lisdexamfetamine) | $10, $40 | | Tier 3 (preferred brand Vyvanse) | $50, $100 | | Tier 4 (non-preferred brand Vyvanse) | $100, $150+ |

These are estimates. Your Explanation of Benefits or the Priority Health drug pricing tool gives the exact number.

The Takeda Savings Card

Takeda (the current brand owner after acquiring Shire) offers a co-pay savings card that may reduce out-of-pocket cost to $30 per month for commercially insured patients who are not enrolled in a government program (Medicare, Medicaid, CHIP). [11] The card does not apply to deductible accumulation in most cases. Ask your pharmacist whether your plan is compatible before relying on it.

What Happens Before Your Deductible Resets

If your plan has a $1,500 or $3,000 deductible that has not been met, you pay the negotiated rate for Vyvanse, not the list price, but still potentially $150, $300 per month for the brand. Generic lisdexamfetamine is substantially cheaper in this scenario, often $50, $80 before the deductible is met.

How to Appeal a Vyvanse Denial

Denials happen. They are not final. Federal law gives you the right to an internal appeal and then an external independent review. [12]

Step 1: Get the Denial Letter

The denial letter must state the specific criterion your request failed to meet. Read it carefully. A denial for "step therapy not complete" is different from a denial for "not medically necessary" and requires a different appeal strategy.

Step 2: Gather Clinical Evidence

Strong appeal packages include:

• Your prescriber's clinical notes documenting diagnosis, symptom severity, and functional impairment
• Prior treatment history (doses tried, duration, documented adverse effects or insufficient response)
• Peer-reviewed citations supporting Vyvanse specifically (e.g., lisdexamfetamine's prodrug mechanism reduces misuse potential compared to mixed amphetamine salts, per Biederman et al. [13])
• A letter of medical necessity from your prescriber that is specific, not templated

The letter of medical necessity is the most important document. Vague letters fail. Specific letters, naming the prior drugs tried, exact doses, exact durations, and exact reasons for failure, succeed more often.

Step 3: Request a Peer-to-Peer Review

Your prescriber can request a phone call with Priority Health's medical reviewer. This peer-to-peer call often resolves denials that written appeals alone do not. The prescriber should ask for the call before the internal appeal deadline.

Step 4: External Independent Review

If the internal appeal is denied, request an external independent review. Michigan law requires insurers to accept the external reviewer's decision as binding for most plan types. [14] External reviewers overturn insurer denials in a meaningful portion of cases, particularly when the clinical documentation is complete.

The HealthRX clinical team uses the following decision framework when helping patients appeal Vyvanse denials: (1) confirm the exact denial reason before writing a single word; (2) match every piece of clinical evidence directly to that denial criterion; (3) quantify impairment with a validated scale such as the Adult ADHD Self-Report Scale or the Binge Eating Scale; (4) cite at least one guideline or peer-reviewed source per criterion challenged; and (5) always request the peer-to-peer call before filing the written internal appeal, because oral clarification resolves roughly half of denials without requiring a formal appeal submission.

Vyvanse for ADHD: The Clinical Case That Supports Coverage

Lisdexamfetamine has a substantial evidence base that supports medical necessity arguments in appeal letters.

Efficacy Data

The FDA approval for adult ADHD was supported by two key trials. In the 4-week phase III trial (Adler et al., 2008; N=420), lisdexamfetamine 30 to 70 mg produced significantly greater reductions in ADHD-RS-IV total scores compared to placebo (P<0.001). [15] A longer 6-month open-label maintenance study demonstrated sustained response. [16]

The Prodrug Advantage

Lisdexamfetamine is a prodrug. It is inactive until enzymatically cleaved to d-amphetamine in the gastrointestinal tract. This mechanism means it cannot be insufflated or injected for a rapid-onset high, which distinguishes it pharmacokinetically from immediate-release amphetamine formulations. [13] For patients with documented concerns about diversion or misuse, this is a legitimate medical reason to prefer lisdexamfetamine over mixed amphetamine salts, and that argument is valid in a PA or appeal.

Duration of Action

Vyvanse provides up to 14 hours of coverage. [1] For adults managing workplace demands across a full day, this duration may be clinically meaningful compared to shorter-acting alternatives. Document functional impairment during late-afternoon hours when arguing this point.

Vyvanse for Binge Eating Disorder: Coverage Considerations

BED is the most common eating disorder in the United States, affecting approximately 2.8 million adults, and lisdexamfetamine is the only FDA-approved pharmacotherapy for it. [17]

Coverage Criteria Specific to BED

Insurers covering lisdexamfetamine for BED typically require:

• DSM-5 diagnosis of moderate or severe BED (≥3 binge episodes per week for ≥3 months)
• Prescriber specialty (psychiatry or internal medicine with eating disorder experience is preferred by some plans)
• Evidence that behavioral interventions (cognitive behavioral therapy) have been attempted or are being used concurrently

The Endocrine Society and the American Psychiatric Association both recognize BED as a medical condition requiring evidence-based treatment. [18]

The McElroy Trial in Appeals

As noted above, the key BED trial (McElroy et al., 2016; N=383) showed lisdexamfetamine 50 mg and 70 mg produced a 78.5% and 84.0% responder rate (defined as ≥50% reduction in binge days), respectively, vs. 49.0% for placebo. [9] These numbers are compelling in an appeal context.

Children and Adolescents: Special Coverage Rules

For patients under 18, Priority Health generally follows FDA labeling, which approves Vyvanse for ADHD starting at age 6. [1] Step therapy for pediatric patients often still applies, but exemptions are more readily granted when a child has already failed methylphenidate (a common first-line agent in pediatric ADHD).

The American Academy of Pediatrics 2019 guideline states: "For children aged 6 years and older, medications approved by the US Food and Drug Administration for ADHD are recommended as part of a comprehensive treatment plan." [7] This direct quotation from a major professional society guideline belongs in every pediatric PA request.

For adolescents approaching adulthood, the continuity of care argument (established on a regimen, stable functioning, risk of disruption) is particularly effective in peer-to-peer calls.

Medicare and Medicaid Coverage for Vyvanse

Medicare Part D

Medicare Part D plans cover controlled substances, but lisdexamfetamine's Schedule II status means some plans require additional documentation. Starting January 1, 2025, the Inflation Reduction Act caps Medicare Part D out-of-pocket drug costs at $2,000 per year. [19] For most Medicare beneficiaries, the net annual cost of Vyvanse should fall below that cap. Priority Health does not administer a standalone Medicare Part D plan in all markets; confirm your specific plan documents.

Michigan Medicaid

Michigan Medicaid's Preferred Drug List covers stimulants for ADHD. Lisdexamfetamine is a covered drug but may require PA and step therapy documentation consistent with Michigan DHHS standards. [6] The Medicaid co-pay is minimal (often $1, $4 per prescription for eligible beneficiaries), making cost less of a barrier than administrative approval.

Practical Steps to Get Vyvanse Covered by Priority Health

Getting coverage approved is a process that moves faster when everyone on your care team coordinates.

Checklist for Patients

• Confirm your specific plan's formulary tier for lisdexamfetamine at the Priority Health member portal before your appointment.
• Ask your prescriber to check whether a PA is required before sending the prescription to the pharmacy.
• Bring documentation of any prior stimulant trials to your appointment so the prescriber can include them in the PA submission.
• Ask whether your plan has a step-therapy exemption request process and whether you qualify.
• Apply for the Takeda co-pay savings card at the manufacturer's website if you are commercially insured.

Checklist for Prescribers

• Submit the PA with DSM-5 diagnosis, severity rating, functional impairment measures, and prior treatment history.
• Use the specific drug names, doses, durations, and documented failure reasons, not generic language.
• Request the peer-to-peer call early rather than waiting for the written denial to arrive.
• Include at least one guideline citation (AAP 2019 for pediatric ADHD [7]; FDA label for BED [1]) in the PA justification.